Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EGFR activation limits the response of liver cancer to lenvatinib.
Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, Wang L, Wang S, Wang C, Dias MH, Jochems F, Yang Y, Bosma A, Hijmans EM, de Groot MHP, Vegna S, Cui D, Zhou Y, Ling J, Wang H, Guo Y, Zheng X, Isima N, Wu H, Sun C, Beijersbergen RL, Akkari L, Zhou W, Zhai B, Qin W, Bernards R. Jin H, et al. Among authors: zheng x. Nature. 2021 Jul;595(7869):730-734. doi: 10.1038/s41586-021-03741-7. Epub 2021 Jul 21. Nature. 2021. PMID: 34290403
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.
Wang L, Jin H, Jochems F, Wang S, Lieftink C, Martinez IM, De Conti G, Edwards F, de Oliveira RL, Schepers A, Zhou Y, Zheng J, Wu W, Zheng X, Yuan S, Ling J, Jastrzebski K, Santos Dias MD, Song JY, Celie PNH, Yagita H, Yao M, Zhou W, Beijersbergen RL, Qin W, Bernards R. Wang L, et al. Among authors: zheng j, zheng x. Nat Cancer. 2022 Nov;3(11):1284-1299. doi: 10.1038/s43018-022-00462-2. Epub 2022 Nov 22. Nat Cancer. 2022. PMID: 36414711
Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.
Zhou Y, Wang S, Wu W, Ling J, Li H, Jia Q, Zheng J, Zheng X, Yu R, Wu Q, Shi Y, Lieftink C, Beijersbergen RL, Yuan S, Bernards R, Jin H, Qin W. Zhou Y, et al. Among authors: zheng j, zheng x. EBioMedicine. 2023 Jan;87:104397. doi: 10.1016/j.ebiom.2022.104397. Epub 2022 Dec 8. EBioMedicine. 2023. PMID: 36502574 Free PMC article.
Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARγ and SREBP2.
Wang S, Zhou Y, Yu R, Ling J, Li B, Yang C, Cheng Z, Qian R, Lin Z, Yu C, Zheng J, Zheng X, Jia Q, Wu W, Wu Q, Chen M, Yuan S, Dong W, Shi Y, Jansen R, Yang C, Hao Y, Yao M, Qin W, Jin H. Wang S, et al. Among authors: zheng j, zheng x. JHEP Rep. 2023 Jul 12;5(10):100843. doi: 10.1016/j.jhepr.2023.100843. eCollection 2023 Oct. JHEP Rep. 2023. PMID: 37675273 Free PMC article.
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH, Zhang X, Yang H, Xu XW, Hu ZL, Yan J, Zheng XL, Wei RR, Zhang ZQ, Tang SR, Geng MY, Huang X. Fu XH, et al. Among authors: zheng xl. Acta Pharmacol Sin. 2019 May;40(5):677-688. doi: 10.1038/s41401-018-0108-5. Epub 2018 Sep 17. Acta Pharmacol Sin. 2019. PMID: 30224636 Free PMC article.
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, Yang H, Hao B, Shen YY, Su Y, Cong X, Huang M, Tan M, Ding J, Geng M. Huang X, et al. Among authors: zheng xl. Cell. 2018 Sep 20;175(1):186-199.e19. doi: 10.1016/j.cell.2018.08.058. Epub 2018 Sep 13. Cell. 2018. PMID: 30220457 Free article.
25,099 results
You have reached the last available page of results. Please see the User Guide for more information.